Saturday 17 October 2026
Export DNLI’s income statement to Excel — free account
Denali Therapeutics Inc.
DNLI Healthcare Biotechnology
In the quarter to June 2026, revenue fell 89.7%, EPS grew 5.56%, free cash flow fell 22.9% and total debt fell 1.76%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
17.56
0.78
−4.25%
Follow DNLI
Denali Therapeutics Inc. (DNLI) P/E ratio
Denali Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 215× (December 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 215× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
Low 0.0×
High 215×
Ten-year median
0.0×
Current reading's percentile
89
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DNLI Denali Therapeutics Inc. | n/m |
| CELC Celcuity, Inc. compare | n/m |
| RCUS Arcus Biosciences, Inc. compare | n/m |
| ZLAB Zai Lab Limited Unsponsored ADR compare | n/m |
| XENE Xenon Pharmaceuticals Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| IDYA IDEAYA Biosciences, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 9.7× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)